ACRRM examiner reports · fix it Not specific enough Naming the right idea without the dose, interval, threshold or number that earns the mark.
What it looks like: "Start an antibiotic" or "monitor closely" is the idea, not the answer. Marks go to the exact drug, dose, route, interval or threshold, and the options often differ only in those details.
How to fix it: When options differ only in a number, recall the number before you read them. Learn the doses, intervals and cut-offs from the local guidelines, not the general principle.
The drill: 15 questions Questions from the Rural generalist bank picked because they test this habit. You answer one at a time and see the explanation straight away.
The first 3 are free, below and in the drill with a free account. Any Rural generalist plan opens all 15.
Try 3 now. No account needed. Question 1 of 3 Palliative care
A palliative care patient is using a transdermal fentanyl patch at 25 micrograms/hour with good pain control, but nursing staff report that the patch will not stay attached because of sweating. The team decides to change to an alternative opioid at an equivalent dose. Which of the following is the most appropriate equivalent regimen? A Morphine 60 mg subcutaneously over 24 hours B Controlled-release oxycodone 20 mg orally twice daily C Immediate-release oxycodone 20 mg orally over 24 hours D Hydromorphone 24 mg orally over 24 hours
Pick an answer to see the explanation. Next question →
Question 1 of 3 · Palliative care
A palliative care patient is using a transdermal fentanyl patch at 25 micrograms/hour with good pain control, but nursing staff report that the patch will not stay attached because of sweating. The team decides to change to an alternative opioid at an equivalent dose. Which of the following is the most appropriate equivalent regimen?
Morphine 60 mg subcutaneously over 24 hours Controlled-release oxycodone 20 mg orally twice daily Immediate-release oxycodone 20 mg orally over 24 hours Hydromorphone 24 mg orally over 24 hours Show the answer B. Controlled-release oxycodone 20 mg orally twice daily
Using the ANZCA Faculty of Pain Medicine opioid calculator, transdermal fentanyl 25 micrograms/hour is approximately equivalent to 60 mg oral morphine per 24 hours. Oral oxycodone is about 1.5 times as potent as oral morphine, so 40 mg oxycodone daily (controlled-release 20 mg twice daily) is equivalent to about 60 mg oral morphine. Many clinicians reduce the calculated dose by 25 to 50% for incomplete cross-tolerance when switching, but the controlled-release oxycodone option is the closest equivalent. Subcutaneous morphine is about 2 to 3 times as potent as oral morphine, so 60 mg subcutaneously per day corresponds to roughly 120 to 180 mg oral morphine, a large overdose. Immediate-release oxycodone 20 mg per day is only about 30 mg oral morphine equivalent and would leave her underdosed. Oral hydromorphone is about 5 times as potent as oral morphine, so 24 mg per day equals about 120 mg oral morphine. After removing a fentanyl patch, the subcutaneous depot continues to release drug for 12 to 24 hours, so the new regimen should be started cautiously. References: Faculty of Pain Medicine, ANZCA. Opioid Calculator. Melbourne: ANZCA. Therapeutic Guidelines. Palliative Care: Opioid conversion. Melbourne: Therapeutic Guidelines Limited.
Why not A: Subcutaneous morphine 60 mg per day equals about 120 to 180 mg oral morphine, a large overdose. Why not C: This is only about 30 mg oral morphine equivalent per day, an underdose. Why not D: Oral hydromorphone 24 mg per day equals about 120 mg oral morphine, double the requirement. Question 2 of 3 · Sexual health
A 31-year-old man presents two days after a three-week trip to Thailand with fevers, malaise and migratory polyarthralgia, three days of dysuria with purulent urethral discharge and, over 48 hours, a few small pustules on an erythematous base on his palm and fingers. Temperature is 38.0 degrees, with asymmetric tenderness of the elbows, wrists and knees and no murmur. He has mild asthma and last injected amphetamines six months ago. Haemoglobin is 145 g/L, platelets 450 x 10^9/L, white cells 14.0 x 10^9/L (neutrophils 9.5), GGT 80 U/L and AST 50 U/L; urine microscopy and chest X-ray are normal, blood cultures are negative so far, and swabs and HIV and syphilis serology are pending. What is the most appropriate initial management?
Ceftriaxone 500 mg IM and azithromycin 1 g orally, discharge with GP follow-up for results and contact tracing Admit, give intravenous flucloxacillin, vancomycin and gentamicin and arrange urgent echocardiography Admit and give ceftriaxone 1 g IV daily alone Admit and give ceftriaxone 1 g IV daily with azithromycin 1 g orally as a single dose Show the answer D. Admit and give ceftriaxone 1 g IV daily with azithromycin 1 g orally as a single dose
Urethritis with fever, migratory polyarthralgia or tenosynovitis and acral pustules is the arthritis-dermatitis syndrome of disseminated gonococcal infection. Therapeutic Guidelines recommend admission and intravenous ceftriaxone 1 g daily, continued until 24 to 48 hours after clinical improvement and then completing about 7 days in total, plus a single oral dose of azithromycin 1 g, in keeping with the dual therapy still used for gonorrhoea in Australia. The Australian STI Management Guidelines classify this as a complicated presentation for which specialist advice should be sought. Cultures from all mucosal sites, blood and any joint fluid are needed to guide therapy given rising ceftriaxone and azithromycin resistance in isolates acquired in South East Asia. The single IM dose used for uncomplicated gonorrhoea is inadequate for disseminated infection, and outpatient care is inappropriate. Ceftriaxone alone omits the azithromycin component of Australian dual therapy. Anti-staphylococcal therapy for endocarditis is not supported by the presentation, normal cardiac examination and negative cultures so far, though echocardiography may be considered if he does not settle. References: Therapeutic Guidelines: Antibiotic. Melbourne: Therapeutic Guidelines Limited; current edition. Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM). Australian STI Management Guidelines for use in primary care: gonorrhoea. Sydney: ASHM; current online edition.
Source: Therapeutic Guidelines (Therapeutic Guidelines Ltd), checked Nov 2026
Why not A: A single IM dose with discharge is the regimen for uncomplicated gonorrhoea, not disseminated infection. Why not B: The picture is disseminated gonococcal infection rather than staphylococcal endocarditis. Why not C: Ceftriaxone alone omits the recommended azithromycin. Question 3 of 3 · Aboriginal and Torres Strait Islander health
A 54-year-old Aboriginal woman from Central Australia has chronic hepatitis B. Results: hepatitis B e antigen negative, HBV DNA 850 IU/mL, alanine aminotransferase normal on three occasions over 12 months, and liver stiffness on elastography 5.2 kPa. She is not on antiviral treatment. What ongoing monitoring is most appropriate?
Liver tests and HBV DNA every 6 to 12 months, with no routine liver imaging Liver ultrasound every 6 months, with liver tests and HBV DNA every 6 to 12 months Liver ultrasound with alpha-fetoprotein every 12 months, with liver tests and HBV DNA annually Elastography every 6 months, with ultrasound only if liver stiffness exceeds 9 kPa Show the answer B. Liver ultrasound every 6 months, with liver tests and HBV DNA every 6 to 12 months
Her results show inactive (HBeAg-negative, low viral load, normal ALT) chronic hepatitis B without significant fibrosis, so antiviral treatment is not indicated. However, Australian hepatitis B guidance recommends hepatocellular carcinoma surveillance with 6-monthly liver ultrasound (with or without alpha-fetoprotein) for high-risk groups regardless of disease activity, including Aboriginal and Torres Strait Islander people aged 50 or over. The C4 subgenotype common in Central Australia carries a particularly high cancer risk. Annual imaging is too infrequent, and a normal elastography result does not remove the indication because tumours can arise without cirrhosis. Liver tests and viral load are monitored to detect reactivation needing treatment.
Why not A: As an Aboriginal person aged 50 or over with hepatitis B, she needs liver cancer surveillance even with inactive disease. Why not C: Annual imaging is too infrequent; surveillance ultrasound is 6-monthly. Why not D: Elastography stages fibrosis but does not detect tumours, and her surveillance indication is independent of stiffness. Create a free account to save your results and keep going →
Where the ACRRM examiners flagged it All ACRRM examiner reports →
Fellowship Ready is not affiliated with or endorsed by the ACRRM. Not affiliated with the Australian College of Rural and Remote Medicine.